Drug Makers Fight New Zealand’s Forced Switch To Indian Generics
This article was originally published in PharmAsia News
Executive Summary
Global drug makers are fighting a move by New Zealand to remove certain branded drugs from its drug formulary when generics become available. The country's Pharmaceutical Management Agency recently canceled coverage for AstraZeneca's Losec (omeprazole) for treating acid indigestion and reflux in favor of a generic from India's Dr. Reddy's Laboratories. Pharmac said the switch would save New Zealand $16.7 million over the next five years. AstraZeneca said the decision forces more than half a million New Zealanders to accept the generic or nothing, except for "a government-funded generic alternative produced in India." (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.